StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a report issued on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Up 1.0 %
Shares of PULM stock opened at $2.02 on Friday. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $2.75. The firm has a market cap of $7.38 million, a PE ratio of -0.84 and a beta of 1.00. The stock has a 50 day moving average of $2.06 and a 200-day moving average of $2.03.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) EPS for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%. The business had revenue of $1.55 million for the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Further Reading
- Five stocks we like better than Pulmatrix
- Transportation Stocks Investing
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Why Are These Companies Considered Blue Chips?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- 3 Fintech Stocks With Good 2021 Prospects
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
